Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Faces Laquinimod Setback After High Dose Linked To CV Events

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva will discontinue higher doses of laqunimod in two ongoing studies for multiple sclerosis after cardiovascular events were experienced in eight patients. Trials will continue with a lower dose.

You may also be interested in...



Teva Stumbles, Actelion Rises In MS: Clinical Protocols Lost And Gained

FDA casts a vote of confidence in Actelion's Phase III trial design for its oral multiple sclerosis candidate ponesimod, while Teva loses its special protocol assessment for laquinimod after dosing changes. Plus more regulatory clinical trial news in brief.

Teva Pins Long-Term Hopes In MS On The Return Of Laquinimod

Teva has ambitions to file in 2018 after the Phase III CONCERTO trial reads out in 2017. Firm is studying a higher dose of the drug and relying on a different primary endpoint, hoping to show stronger efficacy over a Phase III trial that failed in 2011.

Disappointing BRAVO Data Raise Doubts About Laquinimod's Chances With FDA

BRAVO goes to show that placebo event rates may be lower than expected in MS trials and that outcomes are tough to predict, say analysts.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS079070

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel